Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer

OBJECTIVE: Oncogenic alternation in RET is one of the important targets of non-small cell lung cancer (NSCLC). Pralsetinib has shown great efficacy in RET fusion-positive NSCLC, but a series of adverse reactions will inevitably occur in the meantime. We aimed to explore the clinical characteristics...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ming, Zhang, Xia, Yan, Huan, Sun, Decong, Yang, Xuejiao, Yuan, Fang, Ju, Yanfang, Wang, Lijie, Wang, Jinliang, Zhao, Wei, Zhang, Dong, Li, Lin, Xu, Xiaoyun, Ma, Junxun, Hu, Yi, Zhang, Xiaotao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625509/
https://www.ncbi.nlm.nih.gov/pubmed/37924363
http://dx.doi.org/10.1007/s00520-023-08125-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625509/
https://www.ncbi.nlm.nih.gov/pubmed/37924363
http://dx.doi.org/10.1007/s00520-023-08125-3

Ejemplares similares